Xenon Pharmaceuticals Statistics
Total Valuation
XENE has a market cap or net worth of $3.68 billion. The enterprise value is $2.44 billion.
| Market Cap | 3.68B |
| Enterprise Value | 2.44B |
Important Dates
The next estimated earnings date is Monday, November 2, 2026, after market close.
| Earnings Date | Nov 2, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
XENE has 96.84 million shares outstanding. The number of shares has increased by 10.31% in one year.
| Current Share Class | 96.84M |
| Shares Outstanding | 96.84M |
| Shares Change (YoY) | +10.31% |
| Shares Change (QoQ) | +14.04% |
| Owned by Insiders (%) | 0.16% |
| Owned by Institutions (%) | 100.43% |
| Float | 90.90M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 4,378.33 |
| PB Ratio | 2.96 |
| P/TBV Ratio | 2.96 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 21.02, with a Debt / Equity ratio of 0.01.
| Current Ratio | 21.02 |
| Quick Ratio | 20.71 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -43.62% and return on invested capital (ROIC) is -29.18%.
| Return on Equity (ROE) | -43.62% |
| Return on Assets (ROA) | -28.02% |
| Return on Invested Capital (ROIC) | -29.18% |
| Return on Capital Employed (ROCE) | -35.31% |
| Weighted Average Cost of Capital (WACC) | 7.56% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.11M |
| Employee Count | 370 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.94M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -2.81% in the last 52 weeks. The beta is 0.60, so XENE's price volatility has been lower than the market average.
| Beta (5Y) | 0.60 |
| 52-Week Price Change | -2.81% |
| 50-Day Moving Average | 56.43 |
| 200-Day Moving Average | 53.10 |
| Relative Strength Index (RSI) | 24.29 |
| Average Volume (20 Days) | 2,637,379 |
Short Selling Information
The latest short interest is 6.44 million, so 6.66% of the outstanding shares have been sold short.
| Short Interest | 6.44M |
| Short Previous Month | 6.34M |
| Short % of Shares Out | 6.66% |
| Short % of Float | 7.09% |
| Short Ratio (days to cover) | 10.25 |
Income Statement
| Revenue | n/a |
| Gross Profit | -352.49M |
| Operating Income | -441.59M |
| Pretax Income | -411.14M |
| Net Income | -409.20M |
| EBITDA | -439.19M |
| EBIT | -441.59M |
| Earnings Per Share (EPS) | -$4.73 |
Balance Sheet
The company has $930.69 million in cash and $6.42 million in debt, with a net cash position of $1.24 billion or $12.79 per share.
| Cash & Cash Equivalents | 930.69M |
| Total Debt | 6.42M |
| Net Cash | 1.24B |
| Net Cash Per Share | $12.79 |
| Equity (Book Value) | 1.24B |
| Book Value Per Share | 12.84 |
| Working Capital | 900.86M |
Cash Flow
In the last 12 months, operating cash flow was -$337.52 million and capital expenditures -$1.01 million, giving a free cash flow of -$338.53 million.
| Operating Cash Flow | -337.52M |
| Capital Expenditures | -1.01M |
| Depreciation & Amortization | 2.40M |
| Net Borrowing | n/a |
| Free Cash Flow | -338.53M |
| FCF Per Share | -$3.50 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
XENE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -10.31% |
| Shareholder Yield | n/a |
| Earnings Yield | -11.11% |
| FCF Yield | -9.19% |
Analyst Forecast
The average price target for XENE is $74.31, which is 95.45% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $74.31 |
| Price Target Difference | 95.45% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 19 |
| Revenue Growth Forecast (3Y) | 211.18% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
XENE has an Altman Z-Score of 40.57 and a Piotroski F-Score of 2.
| Altman Z-Score | 40.57 |
| Piotroski F-Score | 2 |